What is the next best step in managing an elderly woman with stage 4 chronic kidney disease, hypertension, anemia, macular degeneration, persistent non‑productive cough, body aches, low‑grade fever, negative COVID test and chest X‑ray, after brief improvement with benzonatate (Tessalon) and acetaminophen (Tylenol)?

Next Best Step in Management

The next best step is to perform spirometry and initiate an empiric trial for upper airway cough syndrome (UACS) with a first-generation antihistamine-decongestant combination, while simultaneously evaluating and treating her anemia according to KDIGO guidelines. 1

Immediate Diagnostic Priorities

Complete the Chronic Cough Work-Up

• Spirometry is mandatory for all patients with chronic cough (>8 weeks) to detect obstructive airway disease that may not be apparent on chest radiography alone. 2
• This patient's cough has persisted for approximately 3 weeks total (initial 2-week illness plus 1 week recurrence), approaching the threshold for chronic cough evaluation. 1, 3
• Normal chest X-ray has only 64% negative predictive value for pulmonary causes of chronic cough, but advanced imaging (HRCT) is not indicated at this stage because she lacks red-flag features and has not yet completed empiric treatment trials. 1

Evaluate the Anemia Comprehensively

• Obtain complete blood count with differential, absolute reticulocyte count, serum ferritin, transferrin saturation (TSAT), serum vitamin B12, and folate levels as recommended by KDIGO for anemia evaluation in CKD stage 4. 2
• Her pallor suggests worsening anemia, which in CKD stage 4 is typically multifactorial (erythropoietin deficiency, iron deficiency, chronic inflammation). 2, 4
• Iron deficiency itself can cause chronic drug-resistant cough through potentiation of airway inflammation, making anemia correction potentially therapeutic for both conditions. 5

Systematic Empiric Treatment Algorithm

First-Line: Upper Airway Cough Syndrome

• UACS accounts for 44% of chronic cough cases and should be the first empiric trial even without prominent nasal symptoms, as "silent UACS" can present with cough alone. 1, 3
• Initiate a first-generation antihistamine combined with a decongestant (e.g., brompheniramine-pseudoephedrine) for 2-4 weeks. 1, 3
• Add intranasal corticosteroids if any rhinitis features emerge during treatment. 1

Medication Review

• Review and discontinue ACE inhibitors if present, as they cause cough in 5-50% of users; resolution typically occurs within 26 days (range up to 40 weeks). 1, 3
• Verify that her antihypertensive regimen does not include ACE inhibitors, which are common in CKD patients. 3

Second-Line: Asthma Evaluation

• If UACS treatment fails after 2-4 weeks, proceed to bronchodilator trial to address possible cough-variant asthma, which can present without wheezing. 1, 3
• Bronchial provocation testing (methacholine challenge) is indicated if the bronchodilator trial fails, as normal spirometry does not exclude asthma-related cough. 1, 3

Third-Line: GERD Consideration

• Do NOT prescribe proton-pump inhibitors empirically for unexplained chronic cough lacking gastrointestinal symptoms, per CHEST guidelines. 2, 1
• GERD therapy should only be initiated if she develops reflux symptoms or after UACS and asthma trials have failed. 1, 3

Anemia Management in CKD Stage 4

Iron Repletion Strategy

• If ferritin <100 ng/mL or TSAT <20%, initiate iron therapy before considering erythropoiesis-stimulating agents (ESAs). 2
• Intravenous iron (200 mg weekly for 3 weeks) is preferred over oral iron in CKD stage 4 due to better absorption and tolerance. 2
• Iron correction may independently improve her cough if iron deficiency is contributing to airway inflammation. 5

ESA Therapy Considerations

• ESA therapy should be individualized based on hemoglobin <10 g/dL, rate of decline, prior iron response, transfusion risk, and anemia symptoms (fatigue, dyspnea). 2
• Target hemoglobin 10-11.5 g/dL, not >13 g/dL, as higher targets increase cardiovascular risk without improving quality of life. 2, 6

Re-Evaluation Timeline

• Schedule follow-up in 2-4 weeks to assess cough response to UACS therapy and review anemia laboratory results. 1, 3
• If cough persists after completing UACS trial, advance to asthma-focused evaluation rather than ordering HRCT prematurely. 1
• If cough remains after all three empiric trials (UACS, asthma, GERD) over 8-12 weeks, then consider HRCT to evaluate for bronchiectasis, interstitial lung disease, or occult masses. 1, 3

Common Pitfalls to Avoid

• Do not order HRCT before completing empiric treatment trials in the absence of red-flag features (hemoptysis, age >45 with smoking history, marked dyspnea, hoarseness, systemic symptoms, recurrent pneumonia). 1
• Do not assume the cough is solely due to a viral illness given its recurrent pattern and her multiple comorbidities; systematic evaluation is required. 1, 3
• Do not overlook the anemia as a potential contributor to both her symptoms and cough pathophysiology. 5
• Do not prescribe antibiotics for this non-productive cough without fever, focal findings, or radiographic pneumonia. 3